The Elliot's Neurological Specialties clinic combines medical treatments to slow MS progression with holistic approaches to ...

Foralumab stabilized disability for 6 months in all 10 people with nonactive SPMS who took part in an expanded access program, a study found.

Should multiple sclerosis (MS) patients stop disease-modifying treatment (DMT) as they get older? The answer depends on several factors, noted John Corboy, MD, of the Rocky Mountain MS Center at the ...

Multiple sclerosis (MS) treatment could be on the brink of a significant breakthrough thanks to innovative research by Immunic Therapeutics. Speaking to Fierce Pharma, CEO Daniel Vitt shares insights ...

MS is an autoimmune disorder in which the immune system attacks myelin, the protective covering of nerve fibres in the brain ...

Cladribine, a nucleotide (deoxyadenosine) analogue, inhibits deoxyribonucleic acid (DNA) synthesis in proliferating lymphocytes, causing DNA damage and depleting their number by apoptosis and ...

PARIS — The first real guidelines on the use of disease-modifying therapies in multiple sclerosis (MS) have been released by a European joint venture between the European Committee for Research and ...

Multiple sclerosis (MS) is a debilitating autoimmune disease of the brain and spinal cord. The disease can affect everyone differently, but depending on the progression and severity of the disease, ...

Multiple sclerosis (MS) is a chronic disease of the central nervous system that causes disruptions in the flow of information within the brain and between the brain and body, eventually causing ...

Significantly higher levels of HRQoL were reported in patients who lived in cities, had lower MS severity and fatigue, had higher cognitive processing speed, and had achieved higher educational ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. March is Multiple Sclerosis Awareness Month, a time to ...